NASDAQ:TTOO T2 Biosystems (TTOO) Stock Price, News & Analysis → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free TTOO Stock Alerts $5.09 +0.14 (+2.83%) (As of 02:29 PM ET) Add Compare Share Share Today's Range$4.95▼$5.4050-Day Range$2.72▼$6.0652-Week Range$2.60▼$70.00Volume139,694 shsAverage Volume331,176 shsMarket Capitalization$28.05 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get T2 Biosystems alerts: Email Address T2 Biosystems MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside41.1% Downside$3.00 Price TargetShort InterestBearish22.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector909th out of 931 stocksSurgical & Medical Instruments Industry99th out of 101 stocks 1.0 Analyst's Opinion Consensus RatingT2 Biosystems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageT2 Biosystems has only been the subject of 1 research reports in the past 90 days.Read more about T2 Biosystems' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted22.49% of the float of T2 Biosystems has been sold short.Short Interest Ratio / Days to CoverT2 Biosystems has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in T2 Biosystems has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldT2 Biosystems does not currently pay a dividend.Dividend GrowthT2 Biosystems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TTOO. Previous Next 3.2 News and Social Media Coverage News SentimentT2 Biosystems has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for T2 Biosystems this week, compared to 2 articles on an average week.Search Interest10 people have searched for TTOO on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows5 people have added T2 Biosystems to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, T2 Biosystems insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of T2 Biosystems is held by insiders.Percentage Held by InstitutionsOnly 23.18% of the stock of T2 Biosystems is held by institutions.Read more about T2 Biosystems' insider trading history. Previous Next N/A Earnings and Valuation Read more about T2 Biosystems' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About T2 Biosystems Stock (NASDAQ:TTOO)T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More TTOO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Stock News HeadlinesMay 25 at 7:00 PM | finance.yahoo.comT2 Biosystems, Inc. (TTOO)May 22, 2024 | msn.comT2 Biosystems regains compliance with Nasdaq rule on market value of listed securitiesMay 22, 2024 | globenewswire.comT2 Biosystems Regains Compliance with Nasdaq Continued Listing RequirementsMay 21, 2024 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) Stock Price Passes Above 50-Day Moving Average of $3.46May 17, 2024 | globenewswire.comT2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 15, 2024 | finance.yahoo.comSector Update: Health Care Stocks Advance Late Wednesday AfternoonMay 15, 2024 | globenewswire.comT2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 14, 2024 | finance.yahoo.comT2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common StockMay 14, 2024 | globenewswire.comT2 Biosystems Announces CRG's Conversion from Preferred Stock to Common StockMay 7, 2024 | markets.businessinsider.comT2 Biosystems: Hold Rating Maintained Amid Growth Prospects and Profitability ConcernsMay 7, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces First Quarter 2024 Financial ResultsMay 7, 2024 | msn.comT2 Biosystems, Inc. (NASDAQ:TTOO) Q1 2024 Earnings Call TranscriptMay 7, 2024 | globenewswire.comT2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme DiseaseMay 7, 2024 | finance.yahoo.comT2 Biosystems Inc (TTOO) Q1 2024 Earnings Call Transcript Highlights: Revenue Growth Amidst ...May 6, 2024 | investorplace.comTTOO Stock Earnings: T2 Biosystems Misses EPS, Beats Revenue for Q1 2024May 6, 2024 | markets.businessinsider.comT2 Biosystems is about to announce its earnings — here's what Wall Street expectsMay 6, 2024 | marketwatch.comT2 Biosystems Shares Soar on Narrower 1Q Loss, Plus Debt-to-Equity and Distribution PactsMay 6, 2024 | globenewswire.comT2 Biosystems Announces Commercial Expansion Through Middle East DistributorMay 6, 2024 | globenewswire.comT2 Biosystems Announces First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comT2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into EquityMay 3, 2024 | msn.comT2 Biosystems Q1 Earnings PreviewApril 24, 2024 | globenewswire.comT2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024April 13, 2024 | investing.comT2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceApril 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityApril 11, 2024 | globenewswire.comT2 Biosystems Shareholders Vote for CRG Debt Conversion into EquitySee More Headlines Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/28/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees113Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside-43.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,080,000.00 Net Margins-636.09% Pretax Margin-636.09% Return on EquityN/A Return on Assets-130.45% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.19 Sales & Book Value Annual Sales$7.19 million Price / Sales4.05 Cash FlowN/A Price / Cash FlowN/A Book Value($6.91) per share Price / Book-0.76Miscellaneous Outstanding Shares5,510,000Free Float5,506,000Market Cap$29.09 million OptionableOptionable Beta0.05 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. John J. Sperzel III (Age 61)B.Sc., President, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 66)Chief Financial Officer Comp: $581kMr. Michael Terrence Gibbs Esq. (Age 53)Senior VP, General Counsel & Company Secretary Comp: $622.6kMs. Kelley J. Morgan (Age 48)Chief People Officer Mr. Brett A. Giffin (Age 65)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 59)Senior Vice President of Science Research & Development More ExecutivesKey CompetitorsSeaStar MedicalNASDAQ:ICUSpectral AINASDAQ:MDAINeuroOne Medical TechnologiesNASDAQ:NMTCFemasysNASDAQ:FEMYAkiliNASDAQ:AKLIView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 3,018 shares on 5/20/2024Ownership: 0.238%Group L.P. CrSold 59,812 sharesTotal: $1.14 M ($19.00/share)Group L.P. CrSold 2,500 sharesTotal: $62,500.00 ($25.00/share)Group L.P. CrSold 63,382 sharesTotal: $1.90 M ($30.00/share)Group L.P. CrSold 104,014 sharesTotal: $3.85 M ($37.00/share)View All Insider TransactionsView All Institutional Transactions TTOO Stock Analysis - Frequently Asked Questions Should I buy or sell T2 Biosystems stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares. View TTOO analyst ratings or view top-rated stocks. What is T2 Biosystems' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for T2 Biosystems' shares. Their TTOO share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 41.1%. View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts. How have TTOO shares performed in 2024? T2 Biosystems' stock was trading at $6.28 at the beginning of 2024. Since then, TTOO shares have decreased by 18.9% and is now trading at $5.09. View the best growth stocks for 2024 here. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our TTOO earnings forecast. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) released its earnings results on Monday, May, 6th. The medical equipment provider reported ($2.66) EPS for the quarter. The medical equipment provider earned $2.06 million during the quarter. When did T2 Biosystems' stock split? Shares of T2 Biosystems reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems updated its FY 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.0 million-$11.0 million, compared to the consensus revenue estimate of $10.5 million. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.24%). Insiders that own company stock include Alec Barclay, Brett A Giffin, Group LP Cr, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs. View institutional ownership trends. How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTOO) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
